Modeling Hematopoiesis in MDS and AML with QSP
Discover a mechanistic QSP platform model of hematopoiesis to evaluate therapies in MDS and AML,…
CertaraMay 1, 2026
IO Simulator: A QSP Platform for Immuno-Oncology
This poster showcases how IO Simulator predicts immunotherapy response and supports combination design and biomarker…
CertaraApril 30, 2026
QSP at an inflection point: Scaling impact
The QSP Summit at Certainty US 2026 brought together industry leaders to explore how Quantitative…
CertaraApril 29, 2026
From models to impact: What QSPC 2026 revealed about the future of drug development
Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…
CertaraApril 28, 2026
Modeling Hope: From Patient to Scientist Ellen Swanson on QSP, Breast Cancer, and Hope Through Science
Ellen Swanson, QSP Senior Scientist at Certara, shares her personal journey from breast cancer diagnosis…
CertaraApril 16, 2026
Portfolio Prioritization for Large and Small Pharma Using Early-Stage Biosimulation
Learn how early-stage biosimulation and mechanistic modeling enable smarter portfolio prioritization before IND-enabling studies. Watch…
CertaraMarch 25, 2026
ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD
Learn how model-informed drug development (MIDD) and quantitative systems pharmacology (QSP) support antibody-drug conjugate (ADC)…
CertaraMarch 13, 2026
Accelerate Decisions with Certara IQ™: Scalable, AI-Driven QSP for Drug Development
Discover how Certara's AI-powered QSP modeling software, Certara IQ is overcoming challenges in drug development…
CertaraFebruary 17, 2026
